Heart failure with improved ejection fraction

clinical characteristics, correlates of recovery, and survival

Viorel Florea, Thomas S. Rector, Inder Anand, Jay N Cohn

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background - Heart failure with recovered or improved ejection fraction (HFiEF) has been proposed as a new category of HF. Whether HFiEF is clinically distinct from HF with persistently reduced ejection fraction remains to be validated. Methods and Results - Of the 5010 subjects enrolled in the Valsartan Heart Failure Trial (Val-HeFT), 3519 had a baseline left ventricular EF of <35% and a follow-up echocardiographic assessment of EF at 12 months. Of these, 321 (9.1%) patients who had a 12-month EF of >40% constituted the subgroup with HFiEF. EF improved from 28.7±5.6% to 46.5±5.6% in the subgroup with HFiEF and remained reduced (25.2±6.2% and 27.5±7.1%) in the subgroup with HF with reduced ejection fraction. The group with HFiEF had a less severe hemodynamic, biomarker, and neurohormonal profile, and it was treated with a more intense HF medication regimen. Subjects who had higher blood pressure and those treated with a β-blocker or randomized to valsartan had greater odds of being in the HFiEF group, whereas those with an ischemic pathogenesis, a more dilated left ventricle, and a detectable hs-troponin had lower odds of an improvement in EF. Recovery of the EF to >40% was associated with a better survival compared with persistently reduced EF. Conclusions - Our data support HFiEF as a stratum of HF with reduced ejection fraction with a more favorable outcome, which occurs in a minority of patients with HF with reduced ejection fraction who have a lower prevalence of ischemic heart disease, a less severe hemodynamic, biomarker, and neurohormonal profile, and who are treated with a more intense HF medication regimen.

Original languageEnglish (US)
JournalCirculation: Heart Failure
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Heart Failure
Survival
Valsartan
Biomarkers
Hemodynamics
Troponin
Heart Ventricles
Myocardial Ischemia
Hypertension

Keywords

  • biomarker
  • blood pressure
  • heart failure
  • prognosis
  • valsartan

Cite this

Heart failure with improved ejection fraction : clinical characteristics, correlates of recovery, and survival. / Florea, Viorel; Rector, Thomas S.; Anand, Inder; Cohn, Jay N.

In: Circulation: Heart Failure, Vol. 9, No. 7, 01.07.2016.

Research output: Contribution to journalArticle

@article{7b3d367606994e789b2850ba8e136858,
title = "Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival",
abstract = "Background - Heart failure with recovered or improved ejection fraction (HFiEF) has been proposed as a new category of HF. Whether HFiEF is clinically distinct from HF with persistently reduced ejection fraction remains to be validated. Methods and Results - Of the 5010 subjects enrolled in the Valsartan Heart Failure Trial (Val-HeFT), 3519 had a baseline left ventricular EF of <35{\%} and a follow-up echocardiographic assessment of EF at 12 months. Of these, 321 (9.1{\%}) patients who had a 12-month EF of >40{\%} constituted the subgroup with HFiEF. EF improved from 28.7±5.6{\%} to 46.5±5.6{\%} in the subgroup with HFiEF and remained reduced (25.2±6.2{\%} and 27.5±7.1{\%}) in the subgroup with HF with reduced ejection fraction. The group with HFiEF had a less severe hemodynamic, biomarker, and neurohormonal profile, and it was treated with a more intense HF medication regimen. Subjects who had higher blood pressure and those treated with a β-blocker or randomized to valsartan had greater odds of being in the HFiEF group, whereas those with an ischemic pathogenesis, a more dilated left ventricle, and a detectable hs-troponin had lower odds of an improvement in EF. Recovery of the EF to >40{\%} was associated with a better survival compared with persistently reduced EF. Conclusions - Our data support HFiEF as a stratum of HF with reduced ejection fraction with a more favorable outcome, which occurs in a minority of patients with HF with reduced ejection fraction who have a lower prevalence of ischemic heart disease, a less severe hemodynamic, biomarker, and neurohormonal profile, and who are treated with a more intense HF medication regimen.",
keywords = "biomarker, blood pressure, heart failure, prognosis, valsartan",
author = "Viorel Florea and Rector, {Thomas S.} and Inder Anand and Cohn, {Jay N}",
year = "2016",
month = "7",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.116.003123",
language = "English (US)",
volume = "9",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Heart failure with improved ejection fraction

T2 - clinical characteristics, correlates of recovery, and survival

AU - Florea, Viorel

AU - Rector, Thomas S.

AU - Anand, Inder

AU - Cohn, Jay N

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background - Heart failure with recovered or improved ejection fraction (HFiEF) has been proposed as a new category of HF. Whether HFiEF is clinically distinct from HF with persistently reduced ejection fraction remains to be validated. Methods and Results - Of the 5010 subjects enrolled in the Valsartan Heart Failure Trial (Val-HeFT), 3519 had a baseline left ventricular EF of <35% and a follow-up echocardiographic assessment of EF at 12 months. Of these, 321 (9.1%) patients who had a 12-month EF of >40% constituted the subgroup with HFiEF. EF improved from 28.7±5.6% to 46.5±5.6% in the subgroup with HFiEF and remained reduced (25.2±6.2% and 27.5±7.1%) in the subgroup with HF with reduced ejection fraction. The group with HFiEF had a less severe hemodynamic, biomarker, and neurohormonal profile, and it was treated with a more intense HF medication regimen. Subjects who had higher blood pressure and those treated with a β-blocker or randomized to valsartan had greater odds of being in the HFiEF group, whereas those with an ischemic pathogenesis, a more dilated left ventricle, and a detectable hs-troponin had lower odds of an improvement in EF. Recovery of the EF to >40% was associated with a better survival compared with persistently reduced EF. Conclusions - Our data support HFiEF as a stratum of HF with reduced ejection fraction with a more favorable outcome, which occurs in a minority of patients with HF with reduced ejection fraction who have a lower prevalence of ischemic heart disease, a less severe hemodynamic, biomarker, and neurohormonal profile, and who are treated with a more intense HF medication regimen.

AB - Background - Heart failure with recovered or improved ejection fraction (HFiEF) has been proposed as a new category of HF. Whether HFiEF is clinically distinct from HF with persistently reduced ejection fraction remains to be validated. Methods and Results - Of the 5010 subjects enrolled in the Valsartan Heart Failure Trial (Val-HeFT), 3519 had a baseline left ventricular EF of <35% and a follow-up echocardiographic assessment of EF at 12 months. Of these, 321 (9.1%) patients who had a 12-month EF of >40% constituted the subgroup with HFiEF. EF improved from 28.7±5.6% to 46.5±5.6% in the subgroup with HFiEF and remained reduced (25.2±6.2% and 27.5±7.1%) in the subgroup with HF with reduced ejection fraction. The group with HFiEF had a less severe hemodynamic, biomarker, and neurohormonal profile, and it was treated with a more intense HF medication regimen. Subjects who had higher blood pressure and those treated with a β-blocker or randomized to valsartan had greater odds of being in the HFiEF group, whereas those with an ischemic pathogenesis, a more dilated left ventricle, and a detectable hs-troponin had lower odds of an improvement in EF. Recovery of the EF to >40% was associated with a better survival compared with persistently reduced EF. Conclusions - Our data support HFiEF as a stratum of HF with reduced ejection fraction with a more favorable outcome, which occurs in a minority of patients with HF with reduced ejection fraction who have a lower prevalence of ischemic heart disease, a less severe hemodynamic, biomarker, and neurohormonal profile, and who are treated with a more intense HF medication regimen.

KW - biomarker

KW - blood pressure

KW - heart failure

KW - prognosis

KW - valsartan

UR - http://www.scopus.com/inward/record.url?scp=84979000418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979000418&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.116.003123

DO - 10.1161/CIRCHEARTFAILURE.116.003123

M3 - Article

VL - 9

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 7

ER -